CCL Products (India) (CCL) Q3 25/26 earnings summary

Executive summary

• Achieved Q3 consolidated turnover of INR 1,053 crore (Rs. 1,05,056.46 lakhs), up 38% year-over-year; nine-month turnover at INR 3,239.41 crore (Rs. 3,23,292.96 lakhs), up 42% year-over-year.

• Q3 consolidated net profit rose 59% to INR 100.26 crore (Rs. 10,026.78 lakhs); nine-month net profit up 31% to INR 273.57 crore (Rs. 27,357.38 lakhs).

• Interim dividend of INR 2.75 per equity share declared for FY 2025-26, with record date set for February 10, 2026.

• Un-audited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025, were approved and reviewed by statutory auditors with unmodified reports.

• Domestic branded sales for nine months reached INR 330 crore, with strong growth momentum in India and expansion beyond South India.

Financial highlights

• Q3 EBITDA grew 47% year-over-year to INR 187.56 crore; nine-month EBITDA up 38% to INR 547.6 crore.

• Q3 PBT increased 62% to INR 116.27 crore; nine-month PBT up 37% to INR 337.55 crore.

• Standalone Q3 revenue from operations: Rs. 56,429.43 lakhs; nine months: Rs. 1,65,828.53 lakhs.

• Standalone Q3 net profit: Rs. 3,624.90 lakhs; nine months: Rs. 17,987.54 lakhs.

• Standalone Q3 EPS: Rs. 2.72; consolidated Q3 EPS: Rs. 7.53.

Outlook and guidance

• Volume growth guidance remains at 18%-20% annually; Q4 expected to maintain similar momentum.

• EBITDA growth guidance revised to approximately 25% for FY 2025-26, with 15%-20% targeted for next year, pending market conditions.

• Capacity utilization expected to reach 80%-85% in two years, with further expansion considered thereafter.

• Management continues to monitor regulatory changes, especially new Labour Codes, and has made provisions for potential impacts.